Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Yan Cheng, MD, PhD
Chengdu Kanghong Biotechnology Co.,Ltd.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
179 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Kanghong Investigative Site
CABA, Buenos Aires, Argentina
- Kanghong Investigative Site
CABA, Buenos Aires, Argentina
- Kanghong Investigative Site
CABA, Buenos Aires, Argentina
- Kanghong Investigative Site
Córdoba, Córdoba Province, Argentina
- Kanghong Investigative Site
Rosario, Santa Fe Province, Argentina
- Kanghong Investigative Site
Córdoba, Argentina
- Kanghong Investigative Site
Mendoza, Argentina
- Kanghong Investigative Site
Albury, New South Wales, Australia
- Kanghong Investigative Site
Liverpool, New South Wales, Australia
- Kanghong Investigative Site
Parramatta, New South Wales, Australia
- Kanghong Investigative Site
Strathfield, New South Wales, Australia
- Kanghong Investigative Site
Sydney, New South Wales, Australia
- Kanghong Investigative Site
Adelaide, South Australia, Australia
- Kanghong Investigative Site
Glen Waverley, Victoria, Australia
- Kanghong Investigative Site
Melbourne, Victoria, Australia
- Kanghong Investigative Site
Crawley, Australia
- Kanghong Investigative Site
Sydney, Australia
- Kanghong Investigative Site
Feldkirch, Hessen, Austria
- Kanghong Investigative Site
Klagenfurt, Austria
- Kanghong Investigative Site
Linz, Austria
- Kanghong Investigative Site in Linz
Linz, Austria
- Kanghong Investigative Site
Vienna, Austria
- Kanghong Investigative Site
Vienna, Austria
- Kanghong Investigative Site
Laken, Belgium
- Kanghong Investigative Site
Leuven, Belgium
- Kanghong Investigative Site
Calgary, Alberta, Canada
- Kanghong Ivestigative Site
Vancouver, British Columbia, Canada
- Kanghong Investigative Site
London, Ontario, Canada
- Kanghong Investigative Site
Mississauga, Ontario, Canada
- Kanghong Investigative Site
Toronto, Ontario, Canada
- Kanghong Investigative Site
Montreal, Quebec, Canada
- Kanghong Investigative Site
Montreal, Quebec, Canada
- Kanghong Investigative Site
Sherbrooke, Quebec, Canada
- Kanghong Investigative Site
Santiago, Santiago Metropolitan, Chile
- Kanghong Investigative Site
Santiago, Santiago Metropolitan, Chile
- Kanghong Investigative Site
Barranquilla, Atlántico, Colombia
- Kanghong Investigative Site
Bogotá, Bogota D.C., Colombia
- Kanghong Investigative Site
Cali, Colombia
- Kanghong Investigative Site
Medellín, Colombia
- Kanghong Investigative Site
Bonn, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Sept 2018
- Primary completion
- 25 Sept 2020
- Completion
- 19 May 2021
- Last update posted
- 24 Jun 2021
- Registered enrollment
- 1,157
- Registry id
- NCT03577899
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.